Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reaffirmed by Royal Bank Of Canada in a research note issued on Monday. They currently have a $213.00 target price on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 36.30% from the stock’s current price.

Several other research analysts also recently issued reports on SHPG. Sanford C. Bernstein reiterated a “market perform” rating and set a $210.00 price target on shares of Shire PLC in a research report on Thursday, July 13th. Cantor Fitzgerald reissued a “buy” rating and set a $222.00 price objective on shares of Shire PLC in a report on Thursday, September 14th. HSBC Holdings plc upgraded shares of Shire PLC from a “reduce” rating to a “hold” rating in a research report on Thursday, July 6th. Jefferies Group LLC restated a “buy” rating and issued a $216.00 price objective (down previously from $239.00) on shares of Shire PLC in a research report on Friday, June 9th. Finally, Stifel Nicolaus dropped their target price on shares of Shire PLC from $250.00 to $245.00 and set a “buy” rating for the company in a research note on Friday, June 9th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $220.08.

Shire PLC (SHPG) traded up 0.4610% during trading on Monday, reaching $153.8459. 475,915 shares of the company’s stock traded hands. Shire PLC has a 12 month low of $139.36 and a 12 month high of $198.58.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Equities research analysts expect that Shire PLC will post $14.93 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Royal Bank Of Canada Reaffirms “Buy” Rating for Shire PLC (SHPG)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.watchlistnews.com/royal-bank-of-canada-reaffirms-buy-rating-for-shire-plc-shpg/1605864.html.

A number of institutional investors and hedge funds have recently bought and sold shares of SHPG. Maverick Capital Ltd. boosted its position in shares of Shire PLC by 19.9% during the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after purchasing an additional 322,610 shares in the last quarter. Glenview Capital Management LLC grew its holdings in shares of Shire PLC by 69.7% in the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after buying an additional 707,500 shares during the period. Vanguard Group Inc. grew its holdings in shares of Shire PLC by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after buying an additional 13,665 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Shire PLC by 14.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock valued at $249,577,000 after buying an additional 194,059 shares during the period. Finally, BlackRock Inc. grew its holdings in shares of Shire PLC by 4,217.7% in the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares during the period. Institutional investors own 19.28% of the company’s stock.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.